<?xml version="1.0" encoding="UTF-8"?>
<clinical_study rank="11681">
  <!-- This xml conforms to an XML Schema at:
    http://clinicaltrials.gov/ct2/html/images/info/public.xsd
 and an XML DTD at:
    http://clinicaltrials.gov/ct2/html/images/info/public.dtd -->
  <required_header>
    <download_date>ClinicalTrials.gov processed this data on June 04, 2014</download_date>
    <link_text>Link to the current ClinicalTrials.gov record.</link_text>
    <url>http://clinicaltrials.gov/show/NCT02023606</url>
  </required_header>
  <id_info>
    <org_study_id>810P111</org_study_id>
    <nct_id>NCT02023606</nct_id>
  </id_info>
  <brief_title>Phase I Study to Assess the Absorption, Metabolism, and Excretion of [14C] Labeled SPN-810M.</brief_title>
  <official_title>An Open-Label, Single-Dose, Mass-Balance Study to Assess the Absorption, Metabolism, and Excretion (AME) of [14C] Labeled SPN-810M in Healthy Adult Male Volunteers.</official_title>
  <sponsors>
    <lead_sponsor>
      <agency>Supernus Pharmaceuticals, Inc.</agency>
      <agency_class>Industry</agency_class>
    </lead_sponsor>
  </sponsors>
  <source>Supernus Pharmaceuticals, Inc.</source>
  <oversight_info>
    <authority>United States: Food and Drug Administration</authority>
    <authority>United Kingdom: Medicines and Healthcare Products Regulatory Agency</authority>
    <has_dmc>No</has_dmc>
  </oversight_info>
  <brief_summary>
    <textblock>
      An Open-Label, Single-Dose, Mass-Balance Study to Assess the Absorption, Metabolism, and
      Excretion of Radio Labeled SPN-810M in Healthy Adult Male Volunteers.
    </textblock>
  </brief_summary>
  <overall_status>Completed</overall_status>
  <start_date>November 2013</start_date>
  <completion_date type="Actual">December 2013</completion_date>
  <primary_completion_date type="Actual">December 2013</primary_completion_date>
  <phase>Phase 1</phase>
  <study_type>Interventional</study_type>
  <study_design>Endpoint Classification: Pharmacokinetics Study, Intervention Model: Single Group Assignment, Masking: Open Label, Primary Purpose: Treatment</study_design>
  <primary_outcome>
    <measure>Urinary and fecal recoveries (mass balance) of total radioactivity.</measure>
    <time_frame>10 days post dose.</time_frame>
    <safety_issue>No</safety_issue>
    <description>C(urine and feces), Ae(urine and feces), CumAe(urine and feces), % Dose(urine and feces), CUM% Dose(urine and feces).</description>
  </primary_outcome>
  <secondary_outcome>
    <measure>Whole blood and plasma partitioning of total radioactivity.</measure>
    <time_frame>10 days post dose.</time_frame>
    <safety_issue>No</safety_issue>
    <description>To determine whole blood and plasma partitioning of total radioactivity</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Pharmacokinetics (PK) of total radioactivity in plasma.</measure>
    <time_frame>10 days post dose.</time_frame>
    <safety_issue>No</safety_issue>
    <description>PK of total radioactivity in plasma (Cmax, Tmax, AUC0-t, AUCinf, Kel, and t1/2).</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>PK of SPN-810 in plasma.</measure>
    <time_frame>10 days post dose.</time_frame>
    <safety_issue>No</safety_issue>
    <description>PK of SPN-810 in plasma (Cmax, Tmax, AUC0-t, AUCinf, Kel, and t1/2).</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>PK of the major metabolites of SPN-810 in plasma.</measure>
    <time_frame>10 days post dose.</time_frame>
    <safety_issue>No</safety_issue>
    <description>PK of the major metabolites of SPN-810 in plasma (Cmax, Tmax, AUC0-t, AUCinf, Kel, and t1/2).</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Metabolites of SPN-810 in plasma, urine and feces</measure>
    <time_frame>10 days post dose.</time_frame>
    <safety_issue>No</safety_issue>
    <description>To characterize and identify the metabolites of SPN-810 in plasma, urine and feces.</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Safety and tolerability of SPN-810.</measure>
    <time_frame>10 days post dose.</time_frame>
    <safety_issue>Yes</safety_issue>
    <description>To assess the safety and tolerability of SPN-810 by collecting Adverse Events.</description>
  </secondary_outcome>
  <number_of_arms>1</number_of_arms>
  <enrollment type="Actual">7</enrollment>
  <condition>Impulsive Aggression Comorbid With ADHD</condition>
  <arm_group>
    <arm_group_label>SPN-810M</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
    <description>Single dose of 20 mL solution containing 50 mg of SPN-810M and no less than 8.5 MBq (225 µCi) carbon-14 (14C)-SPN-810M, and no more than 11.3 MBq (305 µCi) [14C] SPN-810M.</description>
  </arm_group>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>SPN-810M</intervention_name>
    <arm_group_label>SPN-810M</arm_group_label>
  </intervention>
  <eligibility>
    <criteria>
      <textblock>
        Key Entry:

          1. Healthy males.

          2. Aged 30 to 55 years.

          3. Considered medically healthy by the Investigator via assessment of physical
             examination, medical history, clinical laboratory tests, urinalysis, vital signs, and
             electrocardiogram.

          4. Able to voluntarily provide written informed consent to participate in the study.
      </textblock>
    </criteria>
    <gender>Male</gender>
    <minimum_age>30 Years</minimum_age>
    <maximum_age>55 Years</maximum_age>
    <healthy_volunteers>Accepts Healthy Volunteers</healthy_volunteers>
  </eligibility>
  <overall_official>
    <last_name>Jo Collier, MBChB</last_name>
    <role>Principal Investigator</role>
    <affiliation>Quotient Clinical</affiliation>
  </overall_official>
  <location>
    <facility>
      <name>Quotient Clinical</name>
      <address>
        <city>Ruddington</city>
        <state>Nottingham</state>
        <zip>NG11 6JS</zip>
        <country>United Kingdom</country>
      </address>
    </facility>
  </location>
  <location_countries>
    <country>United Kingdom</country>
  </location_countries>
  <verification_date>December 2013</verification_date>
  <lastchanged_date>December 23, 2013</lastchanged_date>
  <firstreceived_date>December 17, 2013</firstreceived_date>
  <responsible_party>
    <responsible_party_type>Sponsor</responsible_party_type>
  </responsible_party>
  <keyword>Impulsive Aggression , ADHD</keyword>
  <is_fda_regulated>Yes</is_fda_regulated>
  <is_section_801>No</is_section_801>
  <has_expanded_access>No</has_expanded_access>
  <condition_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm  -->
    <mesh_term>Aggression</mesh_term>
  </condition_browse>
  <!-- Results have not yet been posted for this study                                -->
</clinical_study>
